Cyclovirobuxine-D sustained-release micro-pill capsules and preparation method thereof

Abstract

The invention relates to a buxine slow-release micro-pill capsule and a method for preparing the same. A slow-release micro-pill consisting of a hollow pill core, a main drug layer using Cyclovirobuxine D as an active ingredient and slow-release preparation auxiliary material layer is encapsulated into a capsule to prepare the buxine slow-release micropill capsule; the hollow pill core, the Cyclovirobuxine D as a main drug and the slow-release preparation auxiliary materials comprise the following weight percent: 70 to 95 percent of the hollow pill core, 1 to 5 percent of the Cyclovirobuxine D and the 4 to 25 percent of the slow-release preparation auxiliary materials; and the slow-release preparation auxiliary materials comprise acrylic resin as an adhesive, ethyl cellulose as a coating material, dibutyl sebacate as a plasticizer and talcum powder as a lubricant for encapsulation. The method has good repeatability; and the buxine slow-release micro-pill capsule has even products, good slow release effect and high bioavailability.

Description

(1) Technical field: [0001] The invention relates to an oral chemical medicine slow-release preparation, in particular to a buxyangning sustained-release pellet capsule containing cyclovir buxicine D and a preparation method thereof. (two) background technology: [0002] The main ingredient in Buxus Ning is ring-dimensional boxwood star D (molecular formula: C 26 h 46 N 2 O), ring-dimensional boxwood star D is an effective monomer extracted from boxwood, clinically used for the treatment of chest pain caused by stagnation of qi and blood stasis, pulse knot generation, coronary heart disease arrhythmia, especially as a non-toxic Glycoside cardiotonic drugs are generally concerned. Studies on its cardiovascular pharmacological effects and pharmacodynamics have been very clear. Boxwood is recorded in the "Compendium of Materia Medica" of the Ming Dynasty. Boxwood is mainly used for promoting qi and blood circulation, removing dampness and dredging collaterals. [0003] Cli...

AI Technical Summary

Problems solved by technology

[0005] Currently, the Huang Yang Ning preparation in production is a common preparation, which has problems such as frequent administration and poor patient compliance, which directly affect the clinical efficacy of the drug.

[0006] Chinese patent 03141370 discloses a sustained-release preparation of Buyang Ning, but it uses hypromellose and other auxiliary materials, and adopts simple mixing of medicine and auxiliary materials, and the tabletting method is basically the same as that of ordinary tablets, and there is a problem of easy mixing Disadvantages such as unevenness, poor sustained release effect, low bioavailability, poor tablet compression effect, and easy adhesion of capsule drugs

[0007] People such as Ma Fengyu ("Chinese Medicine Journal", April 2008) prepared Huang Yangning sustained-release microsphere tablets, but its technology is only suitable for laboratory preparation, and it needs to prepare microspheres after dissolving in acetone and chloroform. Organic solvent residues will be produced in the drug, which seriously affects the safety of the drug. At the same time, due to the large amount of chloroform used, the preparation method cannot be applied to large-scale industrial production; and this process method is coated in the solution, and all the drugs cannot be encapsulated. Affect the yield of the preparation, and because the encapsulation rate is different every time, the product quality cannot be guaranteed

Images